Global Opioid Use Disorder Market to Reach $14.6 Billion by 2033, Driven by Government Investments and Growing Treatment Adoption

The latest report titled Global Opioid Use Disorder Market contains an in-depth analysis of the fundamental parameters contributing to the global Opioid Use Disorder market scenario. This research report offers readers an in-depth interpretation of the dynamics of the Opioid Use Disorder market, including key drivers, opportunities, threats, and challenges. The report also briefly discusses key business strategies, supply-demand ratios, key regions, prominent market players, and offers a future outlook for the overall Opioid Use Disorder industry. The market research report is a prototype 360° overview of the global Opioid Use Disorder industry with estimated market value, share, growth trends, total revenue, competitive overview, prominent manufacturers and buyers, available product types, and end-use applications. reveal.

The global Opioid Use Disorder (OUD) market is projected to grow from USD 5.5 billion in 2024 to USD 14.6 billion by 2033, registering a compound annual growth rate (CAGR) of 11.50%. This significant growth is fueled by increasing government investments, expanding access to medication-assisted treatment (MAT), and rising public awareness initiatives.

Get Free Sampel PDF Copy Of This Report At: https://www.emergenresearch.com/public/request-sample/3783

Government Investments Boosting Market Growth
Governments worldwide are making substantial investments to combat the opioid crisis. These funds are improving treatment facilities, supporting harm reduction programs, and expanding access to critical medications.
In the United States, the opioid crisis has been declared a public health emergency, prompting federal and state agencies to allocate billions in funding. In 2022, over $4 billion was dedicated to programs expanding access to treatments like buprenorphine and methadone. Additionally, the Substance Abuse and Mental Health Services Administration (SAMHSA) provided over $1.5 billion in grants to establish treatment centers and train healthcare professionals.

Other nations are also stepping up efforts. In Canada, the government invested CAD 300 million in harm reduction strategies, including supervised consumption sites and naloxone distribution. In Europe, countries such as Germany and France have increased funding for treatment facilities and awareness programs. These initiatives are strengthening healthcare infrastructure and improving access to life-saving therapies.

Growing Adoption of Medication-Assisted Treatment (MAT)
The rising acceptance of MAT is a major driver of market growth. MAT combines behavioral therapy with FDA-approved medications like buprenorphine, methadone, and naltrexone to help individuals manage opioid dependence. Studies indicate that MAT significantly reduces the risk of overdose deaths and improves recovery outcomes.

Legislative reforms have also supported MAT expansion. In the United States, the Comprehensive Addiction and Recovery Act has increased access to buprenorphine by allowing nurse practitioners and physician assistants to prescribe it. By 2022, over 1.5 million Americans were receiving MAT, a 25% increase from 2018. Similarly, in the UK and Australia, the adoption of MAT has grown by 30% and 35%, respectively, in recent years.

Global organizations like the World Health Organization (WHO) and the United Nations Office on Drugs and Crime (UNODC) are also promoting MAT as an effective treatment option, particularly in low- and middle-income countries where opioid addiction rates are rising. As awareness and accessibility improve, the demand for MAT is expected to increase, driving further market growth.

Challenges: Stigma and Limited Access to Treatment
Despite the progress, stigma and limited treatment availability remain significant barriers. Many individuals struggling with opioid addiction hesitate to seek treatment due to fear of judgment or discrimination. According to SAMHSA, in 2022, 60% of those needing treatment refrained from seeking help due to social stigma.

Access to treatment is another challenge, especially in rural areas. The U.S. Health Resources and Services Administration (HRSA) reported in 2023 that only 27% of rural counties had at least one opioid treatment program, compared to 90% in urban areas. Similar challenges exist in countries like India and parts of Eastern Europe, where inadequate funding and social stigma prevent people from receiving the care they need.

Governments and international agencies are working to address these challenges through anti-stigma campaigns and funding initiatives to expand treatment availability. However, significant gaps remain, and further efforts are needed to ensure equitable access to treatment services.
Market Insights: Buprenorphine Leads, Naltrexone Gaining Popularity
Among OUD medications, buprenorphine holds the largest market share due to its effectiveness in managing withdrawal symptoms and reducing cravings. In the U.S., over 60% of MAT programs utilize buprenorphine-based treatments such as Suboxone and Sublocade. Government policies, including expanded prescribing authority for healthcare providers, have further increased its adoption.

Naltrexone is expected to be the fastest-growing drug segment. Unlike other treatments, it is non-addictive and prevents opioid relapse by blocking opioid receptors in the brain. The increasing use of extended-release formulations like Vivitrol has contributed to its rising popularity. The National Institutes of Health reported a 35% increase in naltrexone prescriptions between 2020 and 2023 in the U.S., with similar trends observed in Canada and Germany.

Request Customization: https://www.emergenresearch.com/public/request-for-customization/3783

Competitive Landscape:
The latest study provides an insightful analysis of the broad competitive landscape of the global Opioid Use Disorder market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report. The report analyzes various elements of the market's competitive scenario, such as the regulatory standards and policies implemented across the industry over recent years. Our team of experts has leveraged several powerful analytical tools, such as Porter's Five Forces analysis and SWOT analysis, to deliver a comprehensive overview of the global Opioid Use Disorder market and pinpoint the fundamental growth trends.

Some of the key companies in the global Opioid Use Disorder Market include:
• Indivior PLC
• Teva Pharmaceutical Industries, Ltd.
• Pfizer, Inc.
• Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
• Alkermes, Inc.
• Orexo US, Inc. (a part of Orexo AB)
• Titan Pharmaceuticals, Inc.
• Omeros Corporation
• Camurus AB
• Hikma Pharmaceuticals PLC
Opioid Use Disorder Market Segmentation Analysis
By Drug Outlook (Revenue, USD Million; 2020-2033)
• Naltrexone
• Buprenorphine
o BELBUCA
o Sublocade
o Suboxone
o Zubsolv
o Others
• Methadone
• Others
By Route of Administration Outlook (Revenue, USD Million; 2020-2033)
• Oral Administration
• Injectable Administration
• Others
By Distribution Channel Outlook (Revenue, USD Million; 2020-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others

Browse Full Report: https://www.emergenresearch.com/public/industry-report/opioid-use-disorder-market

Regional Outlook:
 North America (the U.S., Canada, Mexico)
 Europe (the U.K., Germany, France, Italy)
 Asia Pacific (India, China, Japan, Korea)
 Latin America (Brazil, Argentina, Ecuador, Chile)
 Middle East & Africa (Egypt, Turkey, Saudi Arabia, Iran)

Thank you for reading our report. To know more about the customization feature, please get in touch with us, and our team will ensure the report is customized to meet your requirements.

Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.